[1]胡晓亮,朱永军,张红威.阿托伐他汀联合替罗非班治疗ACS伴心律失常患者的疗效及对心肌酶谱、炎症因子的影响▲[J].内科,2020,15(06):665-668.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.09]
 HU Xiaoliang,ZHU Yongjun,ZHANG Hongwei.Efficacy of atorvastatin combined with tirofiban in the treatment of patients with ACS combined with arrhythmia and its influence on myocardial enzymes and inflammatory factors[J].Internal Medicine of China,2020,15(06):665-668.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.09]
点击复制

阿托伐他汀联合替罗非班治疗ACS伴心律失常患者的疗效及对心肌酶谱、炎症因子的影响▲()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年06
页码:
665-668
栏目:
论著
出版日期:
2020-12-31

文章信息/Info

Title:
Efficacy of atorvastatin combined with tirofiban in the treatment of patients with ACS combined with arrhythmia and its influence on myocardial enzymes and inflammatory factors
文章编号:
1673-7768(2020)06-0665-04
作者:
胡晓亮朱永军张红威
商丘市第一人民医院心血管内三科,河南省商丘市476100
Author(s):
HU Xiaoliang ZHU Yongjun ZHANG Hongwei
The Third Department of Cardiovascular Medicine, Shangqiu First People′s Hospital, Shangqiu 476100, Henan province, China
关键词:
急性冠脉综合征心律失常阿托伐他汀替罗非班心肌酶谱炎症因子
Keywords:
Acute coronary syndrome Arrhythmia Atorvastatin Tirofiban Myocardial enzyme Inflammatory factor
分类号:
R 541.7
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2020.06.09
文献标志码:
A
摘要:
目的探讨阿托伐他汀联合替罗非班治疗急性冠状动脉综合征(ACS)伴心律失常患者的疗效及对患者心肌酶谱、炎症因子的影响。方法选择2018年1月至2019年9月我院收治的ACS伴心律失常患者96例,采用随机数字法分为两组,每组48例。两组患者均给予常规药物(阿托伐他汀等)及经皮冠脉介入(PCI)治疗;观察组患者在此基础上,在PCI术中、术后加用替罗非班治疗。比较两组患者的临床疗效;比较两组患者治疗前后的血清心肌酶谱及炎症因子水平;比较两组患者治疗期间的不良反应发生情况。结果治疗3个月,观察组患者的治疗总有效率(93.8%)显著高于对照组(79.2%),差异有统计学意义(P<0.05)。治疗前,两组患者的血清肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平比较,差异无统计学意义(P>0.05);治疗3个月后,观察组患者的CK、CK-MB、hs-CRP、IL-6水平均显著低于对照组,差异有统计学意义(P<0.05)。治疗期间两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论阿托伐他汀联合替罗非班治疗ACS伴心律失常患者疗效确切,可有效地抑制炎症反应,减轻心肌细胞损伤,治疗安全性高。
Abstract:
ObjectiveTo explore the efficacy of atorvastatin combined with tirofiban in the treatment of patients with acute coronary syndrome (ACS) combined with arrhythmia, and its influence on the myocardial enzymes and inflammatory factors. MethodsA total of 96 patients with ACS combined with arrhythmia admitted to our hospital from January 2018 to September 2019 were selected, and they were divided into two groups by the random number method, with 48 cases in each group. Both groups of patients were given conventional medicines (atovastatin etc.) and percutaneous coronary intervention (PCI) for treatment, based on which patients in the observation group were additionally treated with tirofiban during and after PCI. The clinical efficacy, the serum myocardial enzymes, and inflammatory factors levels before and after treatment, as well as the occurrence of adverse reactions during the treatment, were compared between the two groups. ResultsAfter 3 months of treatment, the total effective rate of treatment in the observation group (93.8%) was significantly higher than that in the control group (79.2%), and the difference was statistically significant (P<0.05). The differences of the serum creatine kinase (CK), creatine kinase isoenzyme (CK-MB), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) levels between the two groups before treatment were not statistically significant (P>0.05). After 3 months of treatment, the levels of CK, CK-MB, hs-CRP and IL-6 in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period (P>0.05). ConclusionAtorvastatin combined with tirofiban has a definite curative effect in the treatment of patients with ACS combined with arrhythmia, which can effectively inhibit inflammation, alleviate myocardial cell damage, and thus it is highly safe for treatment.

相似文献/References:

[1]张喜民,刘文智,豆永强,等.胺碘酮治疗心力衰竭合并室性心律失常63例临床疗效观察[J].内科,2014,(05):552.
[2]孙文静 徐戈*.不同剂量阿托伐他汀短期治疗对急性冠脉综合症患者PCI围手术期血浆sCD163的影响[J].内科,2014,(03):252.
 SUN Wen-jing,XU Ge*.The effect of different doses of short-term atorvastatin on the concentration of plasma sCD163 in patients with acute coronary syndrome during perioperative period of PCI[J].Internal Medicine of China,2014,(06):252.
[3]韦文林 李锦忠 农善华 王英杰.急性冠脉综合征患者β内啡肽和血清脑利尿钠肽的变化及临床意义[J].内科,2014,(03):268.
 WEI Wen-lin,LI Jin-zhong,NONG Shan-hua,et al.Study on changes and clinical significance of beta endorphin and serum brain natriuretic peptide in patients with acute coronary syndrome[J].Internal Medicine of China,2014,(06):268.
[4]李发骥.美托洛尔治疗肺心病并发心律失常56例临床观察[J].内科,2014,(03):300.
 [J].Internal Medicine of China,2014,(06):300.
[5]张晓斌杨京会高宝安.慢性肺源性心脏病82例动态心电图分析[J].内科,2013,(02):162.
 [J].Internal Medicine of China,2013,(06):162.
[6]王惠东 马菊兰 张兆奎.心肌致密化不全并发心律失常的监测与处置[J].内科,2013,(05):501.
 [J].Internal Medicine of China,2013,(06):501.
[7]陆家乾.胺碘酮联合稳心颗粒治疗急性心肌梗死后心律失常65例临床观察[J].内科,2012,(06):603.
 [J].Internal Medicine of China,2012,(06):603.
[8]刘苗矿.胺碘酮治疗心衰并心律失常患者179例临床疗效分析[J].内科,2015,(06):879.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.06.43]
 [J].Internal Medicine of China,2015,(06):879.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.06.43]
[9]郝开颜.应用胺碘酮治疗急诊PCI术后患者心律失常的观察与护理[J].内科,2011,(05):521.
 [J].Internal Medicine of China,2011,(06):521.
[10]潘秀贤,蔡焕荣,李兵.急性冠脉综合征患者血液流变学及超敏C反应蛋白变化分析[J].内科,2010,(01):16.
 [J].Internal Medicine of China,2010,(06):16.

备注/Memo

备注/Memo:
▲基金项目:河南省科技攻关计划项目(201702333)
更新日期/Last Update: 2021-01-11